Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
about
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerSarcosine as a potential prostate cancer biomarker and therapeutic targetImmunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate CancerPSA and beyond: alternative prostate cancer biomarkersEmerging PSA-based tests to improve screeningA critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesVariable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cellsAcousto-microfluidics for screening of ssDNA aptamer.Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.Microarray-based multiplexed scanometric immunoassay for protein cancer markers using gold nanoparticle probesNovel biomarkers for prostate cancer including noncoding transcripts.Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.TET2 binds the androgen receptor and loss is associated with prostate cancer.Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancerGenome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibodyEvolutionary history of tissue kallikreinsAminopeptidase activities as prospective urinary biomarkers for bladder cancer.Multiplex Immunosensor Arrays for Electrochemical Detection of Cancer Biomarker Proteins.Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification.Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.Challenges in clinical prostate cancer: role of imaging.Electrochemiluminescent immunosensor for detection of protein cancer biomarkers using carbon nanotube forests and [Ru-(bpy)(3)](2+)-doped silica nanoparticlesSingle-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer.Biobank resources for future patient care: developments, principles and concepts.Enzyme-triggered gelation: targeting proteases with internal cleavage sitesDiagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments.Molecular genetics of prostate cancer: new prospects for old challengesPolymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levelsProteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activitySurgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cellsMeasurement of biomarker proteins for point-of-care early detection and monitoring of cancerEvaluation of degarelix in the management of prostate cancer.Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.Pericellular proteolysis in cancer
P2860
Q21134794-DFCB5E36-7D41-4D5B-98B5-31AF663F99A9Q24609511-746D89F9-57EC-475E-83AE-1D39B58281E3Q26767044-FBA802E5-AF7A-45FD-9137-FA4C126A7BEEQ26770646-E0F66E20-5BF9-466E-833D-4C96F743EAC4Q26828563-765F7D93-3EBA-4D2B-B2DF-A564E2DFB681Q26862558-1717AE5E-39D0-4387-A4F2-5462DE4C5E0FQ26865810-CAAD00B8-5D04-4E7A-AE40-6431BF640BA8Q28533234-6BCDBBCA-9221-49AE-A09E-83B604EAF8A7Q30381725-416F078A-3A00-4E1D-922F-CF7C88AFEFCCQ30664020-06B5F262-F733-4E3F-A961-F3506027D179Q31044291-EA87AADF-1549-4711-864F-C3F5B0AF4765Q33513706-823A1137-9F66-41AF-8F87-6EC7B4F35306Q33515231-4C3785D0-EFCF-4C77-84AC-75D0355ADE29Q33526707-2F5A8BA5-3FD8-4725-8160-BF7C36EEAC32Q33545711-53217351-8586-459A-BB00-50D51527E547Q33563729-AB83CFD4-19CD-41C2-BAE6-E4F64C3FB641Q33566716-3999AC7C-0503-4EA5-BDBD-7113059EBAF8Q33568125-1E314E74-3302-44EE-891D-97127D01565CQ33684005-79C8B037-8DDE-4C2B-B5B1-B76E894D5A63Q33745045-21931CAC-E17F-47D7-9EE5-B8527625939FQ33762931-025D986F-51F5-4B3F-9380-A898D0EBAE63Q33764870-ADBF6BBB-FB66-41B3-B87B-345E6F6D4DB9Q33790362-419D183E-667B-4420-AD1A-B64BAF3C78E6Q33833602-71B40FE8-9CBC-452E-9C15-AA93EEBB1E50Q33842251-CB3010E1-0BE4-40FF-A5F0-32B8E20B006EQ33945133-43B627BB-4289-4143-98C0-8DDFB2C9D356Q33955975-DF9EEA89-CCA9-48CD-BEFC-8A6756B1588AQ33982421-48B924D5-77FF-41D6-A8D0-EA0ABA4AECA8Q34020952-053B6166-9C7E-4E2D-8673-B2F98ED889DEQ34086670-4C57976C-24F4-4F8C-88AB-AFD6496A74ECQ34122725-C33D096B-1842-4BA0-89A9-070743272B45Q34127462-5BCF4835-4252-4C19-B5F3-791FB35DB217Q34158465-D437FB10-72AB-4E7E-A0F4-FFA24CB3E9D9Q34215885-D55A8C04-B175-4EAF-9436-738C1015D5C4Q34267902-1D6185B2-1C38-4B42-ABE0-0C0C8A42CE8EQ34306116-71D17F3A-2786-4360-B7C9-1DD8127A657BQ34384187-8ABA3834-90A5-48BD-ABA5-B5F43C08D52EQ34417797-EB49C00A-CE73-4DFF-92A8-5506FE7ECAEDQ34417941-1FE0B6BE-F3C8-4467-A546-46FECA68D605Q34430691-936F4976-9AD0-4473-ADE9-93DAA396DA6B
P2860
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@en
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@nl
type
label
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@en
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@nl
prefLabel
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@en
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
@nl
P50
P356
P1476
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
@en
P2093
David Ulmert
P2888
P304
P356
10.1038/NRC2351
P407
P577
2008-04-01T00:00:00Z